Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 70300 Ostrava, Czech Republic; Department of Clinical Pharmacology, Department of Laboratory Medicine, University Hospital Ostrava, 17. listopadu 1790, 70852 Ostrava, Czech Republic.
Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava, Syllabova 19, 70300 Ostrava, Czech Republic.
Biomed Pharmacother. 2021 Jun;138:111446. doi: 10.1016/j.biopha.2021.111446. Epub 2021 Mar 4.
To determine transplacental passage of topiramate and its transport to colostrum, mature maternal milk and breastfed infants, we examined data from 27 women treated with topiramate from 2004 to 2020.
In this cohort study, maternal serum, umbilical cord serum, milk and infant serum levels were measured by gas chromatography in the delivery subgroup, the colostrum subgroup (3-4 days postpartum) and the mature milk subgroup (7-30 days postpartum). Paired umbilical cord serum, maternal serum, breastfed infant serum, and milk levels were used to assess the ratios of umbilical cord/maternal serum, milk/maternal serum and infant/maternal serum levels.
Topiramate levels varied from 1.0 to 7.1 mg/L in maternal serum and from 0.8 to 6.2 mg/L in umbilical cord serum, and the mean umbilical cord/maternal serum ratio was 0.93 ± 0.11. At 3-4 days after delivery, topiramate concentrations were 1.4-8.4 mg/L in maternal serum, 1.5-8.6 mg/L in milk and 0.3-4.4 mg/L in infant serum. The mean milk/maternal serum ratio was 0.99 ± 0.45, and the mean infant/maternal serum ratio was 0.25 ± 0.15. At 7-30 days after delivery, maternal serum levels varied from 1.9 to 9.7 mg/L, milk levels ranged from 2.3 to 10.6 mg/L and infant serum levels ranged from 0.3 to 6.5 mg/L. The mean milk/maternal serum ratio was 1.07 ± 0.31, and the mean infant/maternal serum ratio was 0.51 ± 0.27.
We extended information about free transplacental passage of topiramate and its extensive transport to maternal milk with lower serum concentrations in breastfed infants in the largest group of patients ever reported to our knowledge.
Authors declare that take full responsibility for the data, the analyses and interpretation, and the conduct of the research; that they have full access to all of the data; and that they have the right to publish all data. Authors were not participations in industry-sponsored research and corporate activities for evaluation of a manuscript.
为了确定托吡酯的胎盘转运及其向初乳、成熟母乳和母乳喂养婴儿的转移，我们对 2004 年至 2020 年间接受托吡酯治疗的 27 名女性的数据进行了研究。
在这项队列研究中，我们通过气相色谱法测量了分娩亚组、初乳亚组（产后 3-4 天）和成熟乳亚组（产后 7-30 天）中产妇血清、脐血清、母乳和婴儿血清中的托吡酯水平。使用配对的脐血清、母血清、母乳喂养婴儿血清和母乳水平来评估脐血清/母血清、母乳/母血清和婴儿/母血清比值。
托吡酯在母血清中的浓度范围为 1.0 至 7.1mg/L，在脐血清中的浓度范围为 0.8 至 6.2mg/L，平均脐血清/母血清比值为 0.93±0.11。在产后 3-4 天，托吡酯在母血清中的浓度为 1.4-8.4mg/L，在母乳中的浓度为 1.5-8.6mg/L，在婴儿血清中的浓度为 0.3-4.4mg/L。母乳/母血清的平均比值为 0.99±0.45，婴儿/母血清的平均比值为 0.25±0.15。在产后 7-30 天，母血清中的浓度范围为 1.9 至 9.7mg/L，母乳中的浓度范围为 2.3 至 10.6mg/L，婴儿血清中的浓度范围为 0.3 至 6.5mg/L。母乳/母血清的平均比值为 1.07±0.31，婴儿/母血清的平均比值为 0.51±0.27。
我们扩展了关于托吡酯的自由胎盘转运及其向母乳的广泛转运的信息，并且报告了在我们所知的最大的患者群体中，婴儿血清中的托吡酯浓度较低。
作者对数据、分析和解释以及研究的进行承担全部责任；他们拥有所有数据的访问权；并且有权发表所有数据。作者未参与行业赞助的研究和公司活动以评估稿件。
